User talk:Seaside78

Ed Byrd
Ed Byrd has transformed the performance sports nutrition and dietary supplement industry over the course of a 40 year career with the introduction of two of the top three supplement categories: Creatine (over 100 million kilograms sold since 1992) and nitric oxide (trademarked NO2). Byrd’s formulations have garnered the attention of major pharmaceutical companies, universities, and Nobel Prize winners, including Bristol Myers Squibb, Elan Pharmaceuticals, the Juvenile Diabetes Research Foundation, UCSF, University of Nottingham, and Baylor University. Byrd has been awarded six patents and is associated with multiple clinical trials. Ed Byrd began his career in 1981 with Don Tyson and Associates, pioneer of crystalline, free-form amino acids and amino acid formulas. He rose to VP of Sales and Marketing at Champion Nutrition, which ultimately became Muscle Milk®. He then founded the California Body Club in 1987, developing a crystalline, free-form amino acid formula with the eight essential amino acids, featuring high levels of leucine. This was sourced from biotech corporation, Ajinomoto. During this time, Byrd enhanced this formulation by adding zinc monomethionine and magnesium aspartate, used widely today for athletic performance and known as ZMA. In 1992, Byrd co-founded Experimental & Applied Sciences (EAS), which commercialized creatine monohydrate for strength athletes, selling over 100 million kilos. 700 million bottles have been sold since 1992. The introduction of creatine generated over 110 clinical studies and is now being tested for its application to neurological diseases. EAS also introduced hydroxymethylbutyrate (HMB) in 1996, used to enhance athletic performance. EAS was acquired by Bill Phillips, author of the bestselling book, “Body for Life”, and founder of Muscle Media 2000. Byrd went on to found the Medical Research Institute (MRI) in 1996, inventing and manufacturing Glucotize™, the first controlled-release alpha-lipoic acid for the treatment of diabetic neuropathies. Byrd licensed Glucotize™ to the doctors-only supplement company Xymogen. Glucotize became their number-one selling product. Most notably, Byrd originated and developed NO2(™), the first nitric oxide agonist to improve athletic performance. NO2 generated the highest sales revenue in the history of GNC’s Sports Nutrition Division (5% of GNC’s gross annual revenue in 2004), thus creating the nitric oxide category industrywide. Byrd’s book NO2: The 21 Day Transformation (Medical Research Institute, 2002), sold over 750,000 copies. In 2003, Byrd began investigating Peroxisome proliferator-activated receptors (nuclear receptor proteins that serve as transcription factors regulating gene expression) for athletic performance. He contracted a biotech company to synthesize PPAR delta (GW-501-516) at a cost of $10K for one gram for investigational purposes. In 2005, Byrd introduced a PPAR alpha agonist to enhance the NO2 formulation, known as NO2 Platinum(™). (In 2008, the Salk Institute published the first study to turn “couch potato mice into marathon runners” using GW-501-516.) In 2006 MRI introduced Pterostilbene, the methylated version of Resveratrol, to analytics and specialty food ingredient company Chromadex. In 2007 Byrd teamed up with Glanbia to introduce the first eNOS agonist to enhance blood flow, the third generation of NO2, known as the “NO2 Black Label(™).” In 2012, Byrd founded EAB Labs to study exercise signals responsible for mitochondrial biogenesis and epigenetic changes. EAB Labs also engaged in a joint venture with specialty chemical company Evonik on a novel process for the development of pyrroloquinoline quinone (PQQ) that now has GRAS (Generally Recognized as Safe) approval.

https://patents.justia.com/inventor/edward-a-byrd?page=2 https://www.businesswire.com/news/home/20070605005576/en/Natrol-Acquires-Medical-Research-Institute http://coryholly.com/content/ed-byrd-man-who-put-creatine-map

Your submission at Articles for creation: sandbox (September 8)
 Your recent article submission to Articles for Creation has been reviewed! Unfortunately, it has not been accepted at this time. The reasons left by Robert McClenon were:

The comment the reviewer left was:

Please check the submission for any additional comments left by the reviewer. You are encouraged to edit the submission to address the issues raised and resubmit when they have been resolved.


 * If you would like to continue working on the submission, go to User:Seaside78/sandbox and click on the "Edit" tab at the top of the window.
 * If you now believe the draft cannot meet Wikipedia's standards or do not wish to progress it further, you may request deletion. Please go to User:Seaside78/sandbox, click on the "Edit" tab at the top of the window, add "Db-g7" at the top of the draft text and click the blue "publish changes" button to save this edit.
 * If you do not make any further changes to your draft, in 6 months, it will be considered abandoned and may be deleted.
 * If you need any assistance, you can ask for help at the [//en.wikipedia.org/w/index.php?title=Wikipedia:WikiProject_Articles_for_creation/Help_desk&action=edit&section=new&nosummary=1&preload=Template:Afc_decline/HD_preload&preloadparams%5B%5D=User:Seaside78/sandbox Articles for creation help desk], on the [//en.wikipedia.org/w/index.php?title=User_talk:Robert_McClenon&action=edit&section=new&nosummary=1&preload=Template:Afc_decline/HD_preload&preloadparams%5B%5D=User:Seaside78/sandbox reviewer's talk page] or use Wikipedia's real-time chat help from experienced editors.

Robert McClenon (talk) 20:27, 8 September 2020 (UTC)

Your draft article, User:Seaside78/sandbox


Hello, Seaside78. It has been over six months since you last edited the Articles for Creation submission or Draft page you started, "sandbox".

In accordance with our policy that Wikipedia is not for the indefinite hosting of material deemed unsuitable for the encyclopedia mainspace, the draft has been deleted. If you plan on working on it further and you wish to retrieve it, you can request its undeletion. An administrator will, in most cases, restore the submission so you can continue to work on it.

Thanks for your submission to Wikipedia, and happy editing. Liz Read! Talk! 00:14, 9 March 2021 (UTC)